Warning: The NCBI web site requires JavaScript to function. more...
Towards goal-directed therapy of hepatorenal syndrome: we have the tools but we need the trials.
Mookerjee RP, Jalan R.
Crit Care. 2008;12(2):119. Epub 2008 Mar 19.
Related citations
Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial.
Umgelter A, Reindl W, Wagner KS, Franzen M, Stock K, Schmid RM, Huber W.
Crit Care. 2008;12(1):R4. Epub 2008 Jan 15.
Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites.
Umgelter A, Reindl W, Franzen M, Lenhardt C, Huber W, Schmid RM.
Intensive Care Med. 2009 Jan;35(1):152-6. Epub 2008 Sep 18.
Hepatorenal syndrome and ascites--questions and answers.
Bernardi M, Blendis L, Burroughs AK, Laffi G, Rodes J, Gentilini P.
Liver. 1999;19(1 Suppl):15-74. No abstract available.
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F, Pantea L, Sniderman K.
Hepatology. 2004 Jul;40(1):55-64.
Is there still a need for albumin infusions to treat patients with liver disease?
Ginès P, Arroyo V.
Gut. 2000 May;46(5):588-90. No abstract available.
Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study.
Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, Poynard T, Binn M, Grangé JD, Valla D, Lebrec D.
Gut. 2002 Jan;50(1):90-4.
Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.
Arroyo V, Jiménez W.
J Hepatol. 2000;32(1 Suppl):157-70. Review.
Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis.
Gentilini P, Laffi G, La Villa G, Raggi VC.
Ann Ital Med Int. 1999 Oct-Dec;14(4):264-84. Review.
Pathophysiology, diagnosis and treatment of ascites in cirrhosis.
Arroyo V.
Ann Hepatol. 2002 Apr-Jun;1(2):72-9. Review.
Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.
Arroyo V, Colmenero J.
J Hepatol. 2003;38 Suppl 1:S69-89. Review. No abstract available.
Minimizing ascites. Complication of cirrhosis signals clinical deterioration.
Garcia N Jr, Sanyal AJ.
Postgrad Med. 2001 Feb;109(2):91-6, 101-3. Review.
Ascites and renal functional abnormalities in cirrhosis. Pathogenesis and treatment.
Ginès P, Fernández-Esparrach G, Arroyo V.
Baillieres Clin Gastroenterol. 1997 Jun;11(2):365-85. Review.
[Treatment of ascites, hyponatremia and hepatorenal syndrome in liver cirrhosis].
Ackermann D.
Ther Umsch. 2009 Nov;66(11):747-51. Review. German.
Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome.
Suzuki H, Stanley AJ.
QJM. 2001 Jun;94(6):293-300. Review.
Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis.
Angeli P, Merkel C.
J Hepatol. 2008;48 Suppl 1:S93-103. Epub 2008 Feb 5. Review.
Fluid retention in cirrhosis: pathophysiology and management.
Kashani A, Landaverde C, Medici V, Rossaro L.
QJM. 2008 Feb;101(2):71-85. Epub 2008 Jan 9. Review.
Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.
Singh V, Kumar R, Nain CK, Singh B, Sharma AK.
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):303-7.
Circulatory function and hepatorenal syndrome in cirrhosis.
Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, Milicua JM, Jiménez W, Arroyo V.
Hepatology. 2005 Aug;42(2):439-47.
Diagnosis and therapy of ascites in liver cirrhosis.
Biecker E.
World J Gastroenterol. 2011 Mar 14;17(10):1237-48.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on